Cardiovascular Events According to Inhaler Therapy and Comorbidities in Chronic Obstructive Pulmonary Disease
Eun Kim,Eunyoung Lee,Ji Park,Jae Lee,Hye Choi,Bumhee Park,Seung Sheen,Kwang Park,Chin Rhee,Sang Lee,Kwang Yoo,Joo Park
DOI: https://doi.org/10.2147/copd.s433583
2024-01-20
International Journal of COPD
Abstract:Eun Kyung Kim, 1, &ast Eunyoung Lee, 2, &ast Ji Eun Park, 3, &ast Jae Seung Lee, 4 Hye Sook Choi, 5 Bumhee Park, 6, 7 Seung Soo Sheen, 3 Kwang Joo Park, 3 Chin Kook Rhee, 8 Sang Yeub Lee, 9 Kwang Ha Yoo, 10 Joo Hun Park 3 1 Department of Pulmonology, Allergy and Critical Care Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea; 2 Department of Neurology, McGovern Medical School at UTHealth, Houston, TX, USA; 3 Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Suwon, Republic of Korea; 4 Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; 5 Department of Internal Medicine, Kyung Hee University Medical Center, Seoul, Republic of Korea; 6 Office of Biostatistics, Medical Research Collaborating Center, Ajou Research Institute for Innovative Medicine, Ajou University Medical Center, Suwon, Republic of Korea; 7 Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea; 8 Department of Internal Medicine, Seoul St. Mary's Hospital, Catholic University of Korea, Seoul, Republic of Korea; 9 Department of Internal Medicine, Korea University Anam Hospital, Seoul, Republic of Korea; 10 Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Republic of Korea &astThese authors contributed equally to this work Correspondence: Joo Hun Park, Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Worldcup Road 164, Suwon, Gyeonggi-do, 16499, Republic of Korea, Tel +82-31-219-5116, Fax +82-31-219-5124, Email ; Background: COPD coexists with many concurrent comorbidities. Cardiovascular complications are deemed to be major causes of death in COPD. Although inhaler therapy is the main therapeutic intervention in COPD, cardiovascular events accompanying inhaler therapy require further investigation. Therefore, this study aimed to investigate new development of cardiovascular events according to each inhaler therapy and comorbidities. Methods: This study analyzed COPD patients (age ≥ 40 years, N = 199,772) from the Health Insurance Review and Assessment Service (HIRA) database in Korea. The development of cardiovascular events, from the index date to December 31, 2020, was investigated. The cohort was eventually divided into three arms: the LAMA/LABA group (N = 28,322), the ICS/LABA group (N = 11,812), and the triple group (LAMA/ICS/LABA therapy, N = 6174). Results: Multivariable Cox analyses demonstrated that, compared to ICS/LABA therapy, triple therapy was independently associated with the development of ischemic heart disease (HR: 1.22, 95% CI: 1.04– 1.43), heart failure (HR: 1.45, 95% CI: 1.14– 1.84), arrhythmia (HR: 1.72, 95% CI: 1.41– 2.09), and atrial fibrillation/flutter (HR: 2.31, 95% CI: 1.64– 3.25), whereas the LAMA/LABA therapy did not show a significant association. Furthermore, emergency room visit during covariate assessment window was independently associated with the development of ischemic heart disease, heart failure, arrhythmia, and atrial fibrillation/flutter ( p < 0.05). Conclusion: Our data suggest that cardiovascular risk should be considered in COPD patients receiving triple therapy, despite the confounding bias resulting from disparities in each group. Keywords: COPD, inhaler therapy, cardiovascular event, comorbidities Chronic obstructive pulmonary disease (COPD) is a global health issue with increasing prevalence, morbidity, and mortality. 1,2 COPD coexists with many concurrent co-morbidities, including hypertension, ischemic heart disease, chronic heart failure, osteoporosis, muscle weakness, depression, and lung cancer. 3–5 Cardiovascular complications are deemed to be major causes of death in COPD. 3–5 The development of cardiovascular comorbidities in COPD is explained by several mechanisms, including lung hyperinflation, hypoxemia, pulmonary hypertension, systemic inflammation, oxidative stress, and exacerbations. 6,7 Current guidelines recommend the use of inhaled long-acting bronchodilators in symptomatic COPD patients because beneficial effects of inhaled long-acting bronchodilators including long-acting β2-agonists (LABA) and long-acting muscarinic antagonists (LAMA) in COPD have been documented in several clinical trials. 8–10 Inhaled long-acting bronchodilators can reduce the frequency and severity of acute exacerbati -Abstract Truncated-
respiratory system